v3.26.1
Accounts Receivable
6 Months Ended
Jun. 30, 2026
Receivables [Abstract]  
Accounts Receivable Accounts Receivable
The Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable and allowance for credit losses.
Accounts Receivable as of June 30, 2026 and December 31, 2025 consist of the following:
(in thousands)June 30, 2026December 31, 2025
Oral drug accounts receivable (Specialty Pharmacy)$18,564 $7,457 
Capitated accounts receivable (Patient Services)1,937 3,213
FFS accounts receivable, net (Patient Services)29,385 35,376
Other trade receivables16,463 12,952
Total$66,349 $58,998 
There was no allowance for credit losses as of June 30, 2026 and December 31, 2025.
As of January 1, 2025, the accounts receivable balance amounted to $48,335.
During the three and six months ended June 30, 2026 and 2025, the Company had no net bad debt recoveries and bad debt expense. Credit losses are a result of accounts receivable on completed contracts that were deemed uncollectible during the period.